Want to see NVO full AI Analyst Report?
NVO Stock Chart & Stats
$48.66
$0.95(1.95%)
At close: 4:00 PM EDT
$48.66
$0.95(1.95%)
Day’s Range― - ―
52-Week Range$35.12 - $64.16
Previous CloseN/A
Volume1.15M
Average Volume (3M)13.14M
Market Cap
$170.64B
Enterprise Value$227.20B
Total Cash (Recent Filing)$44.98B
Total Debt (Recent Filing)$140.13B
Price to Earnings (P/E)9.9
Beta1.11
Next Earnings
Nov 04, 2026EPS Estimate
0.74Next Dividend Ex-DateN/A
Dividend Yield4.68%
Share Statistics
EPS (TTM)26.23
Shares Outstanding3,390,128,000
10 Day Avg. Volume12,024,477
30 Day Avg. Volume13,141,788
Financial Highlights & Ratios
PEG Ratio8.16
Price to Book (P/B)7.42
Price to Sales (P/S)4.66
P/FCF Ratio49.64
Enterprise Value/Market Cap1.33
Enterprise Value/Revenue0.69
Enterprise Value/Gross Profit0.86
Enterprise Value/Ebitda1.26
Forecast
1Y Price Target
$42.53Price Target Upside-12.59% Downside
Rating ConsensusHold
Number of Analyst Covering7
EPS Forecast (FY)3.35
Revenue Forecast (FY)$45.73B
Bulls Say, Bears Say
Bulls Say
Exceptional Growth And ProfitabilityNovo combines rapid revenue expansion with unusually high profitability, indicating strong product economics and pricing power in chronic-care medicines. These margins can support substantial reinvestment in manufacturing, commercial expansion and research while providing resilience through normal business-cycle fluctuations.
Leading GLP-1 Market PositionThe strong position across injectable and oral obesity treatments demonstrates substantial commercial execution, brand strength and patient adoption. Oral-market leadership also broadens the addressable market and may help Novo retain relevance as treatment preferences evolve and obesity care expands internationally.
Pipeline And Licensing ExpansionThe HRS-1596 license adds a potential once-weekly oral therapy to Novo’s obesity pipeline and strengthens access to next-generation mechanisms. Although development remains uncertain, the deal broadens future product options and supports ongoing innovation beyond the current semaglutide franchise.
Bears Say
Challenging 2026 OutlookManagement’s flat-to-declining 2026 outlook signals that near-term growth is being pressured by lower realized prices, competition, coverage reductions and semaglutide exclusivity losses. These forces could persist across the next several quarters and make recent exceptional growth harder to sustain.
Higher Leverage And Weaker Cash ConversionThe sharp increase in borrowing reduces financial flexibility relative to the company’s earlier balance-sheet position, while weak free-cash-flow conversion limits the cash cushion behind reported earnings. Continued investment and capital returns will therefore require closer discipline if product conditions soften.
Clinical Pipeline SetbackZEUS weakens the potential contribution of ziltivekimab and highlights the uncertainty of Novo’s expansion into higher-risk disease areas. The result may also increase reliance on obesity and diabetes programs, making successful development and commercialization of replacement pipeline assets more important.
Novo Nordisk News
NVO FAQ
What was Novo Nordisk’s price range in the past 12 months?
Novo Nordisk lowest stock price was $35.12 and its highest was $64.16 in the past 12 months.
What is Novo Nordisk’s market cap?
Novo Nordisk’s market cap is $170.64B.
When is Novo Nordisk’s upcoming earnings report date?
Novo Nordisk’s upcoming earnings report date is Nov 04, 2026 which is in 15 days.
How were Novo Nordisk’s earnings last quarter?
Novo Nordisk released its earnings results on Aug 04, 2026. The company reported $0.955 earnings per share for the quarter, beating the consensus estimate of $0.77 by $0.185.
Is Novo Nordisk overvalued?
According to Wall Street analysts Novo Nordisk’s price is currently Overvalued.
Does Novo Nordisk pay dividends?
Novo Nordisk pays a Semiannually dividend of $0.579 which represents an annual dividend yield of 4.68%. See more information on Novo Nordisk dividends here
What is Novo Nordisk’s EPS estimate?
Novo Nordisk’s EPS estimate is 0.74.
How many shares outstanding does Novo Nordisk have?
Novo Nordisk has 3,390,128,000 shares outstanding.
What happened to Novo Nordisk’s price movement after its last earnings report?
Novo Nordisk reported an EPS of $0.955 in its last earnings report, beating expectations of $0.77. Following the earnings report the stock price went down -5.967%.
Which hedge fund is a major shareholder of Novo Nordisk?
Currently, no hedge funds are holding shares in NVO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Novo Nordisk Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$42.53 (-12.59% Downside)
$42.53 (-12.59% Downside)
Blogger Sentiment
Bullish
NVO Sentiment 66%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Increased
By 2.5M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▼ 0.4%
Last 30 Days ▼ 0.9%
Last 30 Days ▼ 0.9%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-26.93%
12-Months-Change
Fundamentals
Return on Equity
59.09%
Trailing 12-Months
Asset Growth
19.95%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Novo Nordisk
Novo Nordisk A/S is a global pharmaceutical firm dedicated to the investigation, creation, manufacturing, and distribution of medicinal products across a vast international footprint. Its market presence extends throughout Europe, the Middle East, Africa, various parts of Asia (including Mainland China, Hong Kong, and Taiwan), and North America. The company's operations are structured into two principal business units: Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity Care division delivers therapies for diabetes, obesity, cardiovascular ailments, and other emerging therapeutic areas. Meanwhile, the Rare Disease division concentrates on providing treatments for rare blood disorders, uncommon endocrine conditions, and hormone replacement solutions. In addition to its core pharmaceutical offerings, Novo Nordisk produces specialized medical equipment such as insulin pens, growth hormone pens, and injection needles. It also pioneers smart digital solutions for diabetes management, including advanced insulin pens and the Dose Check application, designed to guide insulin dosage. The company engages in strategic alliances, notably a partnership with UNICEF to combat childhood obesity and a collaboration with Valo Health, Inc. to discover and advance novel drug pipelines in the cardiometabolic space. Founded in 1923, Novo Nordisk A/S is headquartered in Bagsvaerd, Denmark.
NVO Company Deck
NVO Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call was broadly constructive, supported by strong GLP-1 volume growth, rapid Wegovy pill uptake in the U.S. and international markets, continued pipeline advancement, Q2 sales growth of 7%, operating profit growth of 11%, and transformation savings ahead of plan. However, the company faces material headwinds from lower realized prices, declining gross margin, U.S. competition and coverage pressure, semaglutide loss of exclusivity, declining international market share, and the unsuccessful ZEUS cardiovascular outcomes trial. Overall, the highlights significantly outweigh the lowlights, although management characterized 2026 as a challenging year.View all NVO earnings summariesNVO Stock 12 Month Forecast
Average Price Target
$42.53
▼(-12.59% Downside)
Technical Analysis
Ownership Overview
―
Insiders
1.65% Mutual Funds
0.26% Other Institutional Investors
97.88% Public Companies and Individual Investors